CDIddy, The secondary endpoints are clinically
Post# of 148184
The secondary endpoints are clinically very important.
If Cytodyn missed primary endpoint (again phase 3/registrational), I would expect EUA and another trial to obtain full approval.
That is unless Cytodyn gets the Gilead Remdesivir red carpet treatment (sarcasm intended in consideration of the last few months).